Grace Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Grace Therapeutics, Inc.'s free cash flow has increased -40.49% from $-14.90M last year to $-8.87M, signaling increasing performance

Grace Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Grace Therapeutics, Inc. has insufficient data to evaluate this check.

Grace Therapeutics, Inc. has a net cash position, so leverage is healthy.

Grace Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Grace Therapeutics, Inc. has insufficient data to evaluate this check.

Grace Therapeutics, Inc.'s short-term assets of $17.38M exceed its short-term liabilities of $2.15M

Grace Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Grace Therapeutics, Inc.'s return on equity of -14.15%, is lower than 15.00%, indicating bad performance

Grace Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Grace Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Grace Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Grace Therapeutics, Inc. has negative free cash flow, indicating cash burn

Grace Therapeutics, Inc.'s yearly earnings has increased -42.81% since last year from $-13.63M to $-7.79M, signaling increasing performance

Grace Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -16.94% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Grace Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Grace Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Grace Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Grace Therapeutics, Inc. has insufficient data to evaluate this check.

Grace Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Grace Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Grace Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Grace Therapeutics, Inc. has insufficient data to evaluate this check.

Grace Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Grace Therapeutics, Inc. has a price-to-book ratio of 0.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Grace Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue